Search Results
Jul 23, 2026, 05:00 ET Moa Technology raises Series C round co-led by Oxford Science Enterprises and Supernova Invest
IP and the progress it has made to become the innovation partner of choice for the crop protection industry. In the last 24 months, Moa has formed R&D collaborations with four leading companies - Nufarm, Gowan, Certis Belchim and Corteva Agriscience - to develop different novel solutions to help farmers
More news about: Moa Technology
Jul 23, 2026, 04:56 ET STARTRADER Ra Mắt SKHY Ngay Sau Khi SK Hynix Niêm Yết Tại Mỹ, Mang Đến Cơ Hội Tiếp Cận Kịp Thời Với Cổ Phiếu AI Hàng Đầu
multimedia:https://www.prnewswire.com/vn/news-releases/u0073u0074u0061u0072u0074u0072u0061u0064u0065u0072u002Du0072u0061u002Du006Du1EAFu0074u002Du0073u006Bu0068u0079u002Du006Eu0067u0061u0079u002D-302833170.htmlSOURCE
More news about: STARTRADER
Jul 23, 2026, 04:53 ET Polylactic Acid Market Size Anticipated to Reach USD 4,829.55 Million by 2036 Driven by Rising Demand for Sustainable Bioplastics and Renewable Packaging Solutions
applications.Growing demand for compostable carrier bags.Rising adoption across agricultural films.Why Does 3D Printing Continue to Dominate End Use?The 3D Printing segment is expected to command the largest end-use share during 2026 as PLA remains one of the most widely
More news about: Future Market Insights
Jul 23, 2026, 04:30 ET FORD AND GEELY AUTO JOIN FORCES IN EUROPE TO PRODUCE NEXT-GENERATION MULTI-ENERGY VEHICLES IN SPAIN
increase of 90%.With a strong focus on technology innovation, electrification, and sustainable mobility, Geely Auto Group operates world-class R&D centers and manufacturing facilities across China, Europe, and key international markets. The Group is committed to delivering safe, high-quality,
More news about: Ford
Jul 23, 2026, 04:30 ET FORD AND GEELY AUTO JOIN FORCES IN EUROPE TO PRODUCE NEXT-GENERATION MULTI-ENERGY VEHICLES IN SPAIN
increase of 90%.With a strong focus on technology innovation, electrification, and sustainable mobility, Geely Auto Group operates world-class R&D centers and manufacturing facilities across China, Europe, and key international markets. The Group is committed to delivering safe, high-quality,
More news about: Ford
Jul 23, 2026, 04:30 ET Ford y Geely Auto unen fuerzas en Europa para producir vehículos multienergía de última generación en España
90%.Con un sólido enfoque en la innovación tecnológica, la electrificación y la movilidad sostenible, Geely Auto Group opera centros de I+D y plantas de fabricación de clase mundial en China, Europa y mercados internacionales clave. El Grupo está comprometido con la entrega de vehículos seguros,
More news about: Ford
Jul 23, 2026, 04:30 ET FORD ET GEELY AUTO S'UNISSENT EN EUROPE POUR PRODUIRE LA PROCHAINE GÉNÉRATION DE VÉHICULES MULTI-ÉNERGIES EN ESPAGNE
annuelle de 90 %. Avec un accent fort sur l'innovation technologique, l'électrification et la mobilité durable, Geely Auto Group exploite des centres de R&D et des installations de fabrication de classe mondiale en Chine, en Europe et sur des marchés internationaux clés. Le Groupe s'engage à proposer des
More news about: Ford
Jul 23, 2026, 04:25 ET 데크라코리아, KTL과 전략적 협력 체결, 유로7 및 탄소규제 대응으로 국내 자동차 부품기업의 유럽 시장 진출 지원
multimedia:https://www.prnewswire.com/kr/news-releases/uB370uD06CuB77CuCF54uB9ACuC544u002Cu002Du006Bu0074u006CuACFCu002DuC804uB7B5uC801u002DuD611uB825u002DuCCB4uACB0u002Cu002DuC720uB85Cu0037u002D-302833140.htmlSOURCE
More news about: DEKRA Korea
Jul 23, 2026, 03:33 ET Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
compelling orexin biology into a new treatment approach for narcolepsy and other sleep-wake disorders," said Johan Luthman, Executive Vice President R&D, Lundbeck. "For people living with narcolepsy, the ability to sustain wakefulness can shape almost every part of daily life. Fast Track designation
More news about: H. Lundbeck A/S
Jul 23, 2026, 03:29 ET Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
compelling orexin biology into a new treatment approach for narcolepsy and other sleep-wake disorders," said Johan Luthman, Executive Vice President R&D, Lundbeck. "For people living with narcolepsy, the ability to sustain wakefulness can shape almost every part of daily life. Fast Track designation
More news about: H. Lundbeck A/S
Jul 23, 2026, 03:00 ET Kavalan Named 'Whisky of the Year' For Second Year Running at IWC 2026
Year:Kavalan Peatist Oloroso Sherry Cask Single Cask Strength Single Malt WhiskyMaster Distiller of the Year:Zerose Yang - Head of R&DAvailability: Kavalan Peatist Oloroso Sherry Cask is available now in Taiwan and selected international markets, including France, Canada,
More news about: Kavalan Whisky
Jul 23, 2026, 03:00 ET Kavalan élu Whisky de l'année pour la deuxième année consécutive lors de l'IWC 2026
Peatist Oloroso Sherry Cask Single Cask Strength Single Malt WhiskyMaître distillateur de l'année : Zerose Yang - Chef de la R&DDisponibilité : le Kavalan Peatist Oloroso Sherry Cask est désormais disponible à Taïwan et sur certains marchés internationaux, notamment
More news about: Kavalan Whisky
Jul 23, 2026, 02:37 ET Stora Enso Half-year Report 2026: Optimising our portfolio and driving results through our own actions
https://mb.cision.com/Public/13589/4376981/b55d5e6ef243b152.pdf STORAENSO RESULTS
More news about: Stora Enso Oyj
Jul 23, 2026, 02:29 ET Stora Enso Half-year Report 2026: Optimising our portfolio and driving results through our own actions
https://mb.cision.com/Public/13589/4376981/b55d5e6ef243b152.pdf STORAENSO RESULTS
More news about: Stora Enso Oyj
Jul 23, 2026, 02:19 ET Scania Performance Summary April - June 2026
truck deliveries, a favourable product mix, continued cost efficiencies and the growing services business. These factors more than offset increased R&D investments and the expenses related to the ramp-up of Scania's industrial hub in China.Truck order intake increased significantly, mainly driven
More news about: Scania
Jul 23, 2026, 02:18 ET Invitation to attend Systemair AB's (publ) AGM
number of members of the Board of Directors,c) proposal for Board fees, with respective allocations to Chairman and other Board members,d) proposal for fee to the Company's auditors,e) proposal for Board of Directors and Chairman, andf) proposal for auditor.The Nominating
More news about: Systemair AB
Jul 23, 2026, 02:08 ET Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
in R&D and innovation.Guided by its innovation and globalization strategy and supported by the strong innovation ecosystem and biopharmaceutical industry environment in Sichuan Province and Chengdu, Haisco continues to increase investment in innovation. The company has built an R&D team
More news about: Haisco Pharmaceutical Group Co., Ltd.
Jul 23, 2026, 02:00 ET Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World's First Fully Recoverable Self-Expanding Dry-Valve TAVR System
developed a comprehensive product pipeline covering all four heart valves — TAVR, TPVR, TMVR, and TTVR —and related accessory products. With global R&D centers in China, the United States, and Israel, the company is committed to providing effective treatment solutions for life-threatening diseases.
More news about: Venus Medtech (Hangzhou) Inc.
Jul 23, 2026, 02:00 ET A Venus Medtech anuncia a conclusão do recrutamento de pacientes para o estudo clínico pivotal na China do Venus-PowerX, o primeiro sistema TAVR com válvula seca autoexpansível totalmente recuperável do mundo
abrangente que inclui todas as quatro válvulas cardíacas — TAVR, TPVR, TMVR e TTVR — e produtos acessórios relacionados. Com centros globais de P&D na China, nos Estados Unidos e em Israel, a empresa está comprometida em oferecer soluções de tratamento eficazes para doenças potencialmente fatais.
More news about: Venus Medtech (Hangzhou) Inc.
Jul 23, 2026, 02:00 ET Venus Medtech anuncia la finalización del reclutamiento de pacientes para el ensayo clínico de Venus-PowerX
productos integral que abarca las cuatro válvulas cardíacas —TAVR, TPVR, TMVR y TTVR— y productos accesorios relacionados. Con centros globales de I+D en China, Estados Unidos e Israel, la compañía está comprometida a proporcionar soluciones de tratamiento eficaces para enfermedades potencialmente mortales.
More news about: Venus Medtech (Hangzhou) Inc.
Jul 23, 2026, 02:00 ET Venus Medtech anuncia que ha finalizado el reclutamiento de pacientes en un ensayo clínico decisivo realizado en China para Venus-PowerX, el primer sistema TAVR del mundo con válvula seca autoexpandible y totalmente recuperable
amplia gama de productos que abarca las cuatro válvulas cardíacas —TAVR, TPVR, TMVR y TTVR—, así como los accesorios relacionados. Con centros de I+D a nivel mundial en China, Estados Unidos e Israel, la compañía se compromete a ofrecer soluciones terapéuticas eficaces para enfermedades que ponen en
More news about: Venus Medtech (Hangzhou) Inc.
Jul 23, 2026, 02:00 ET Venus Medtech annonce la fin du recrutement des patients dans le cadre de l'essai clinique décisif mené en Chine sur le Venus-PowerX, le premier système TAVR au monde à valve sèche auto-expansible et entièrement récupérable
produits couvrant les quatre valves cardiaques, TAVR, TPVR, TMVR et TTVR, et les produits accessoires connexes. Disposant de centres mondiaux de R&D en Chine, aux États-Unis et en Israël, la société s'engage à fournir des solutions de traitement efficaces pour les maladies mortelles.
More news about: Venus Medtech (Hangzhou) Inc.
Jul 23, 2026, 01:05 ET PLATINUM EQUITY AND NESTLÉ TO CREATE PERANEL, A $5.6 BILLION LEADER IN WATER AND PREMIUM BEVERAGES
will have full flexibility to invest in its brands and pursue growth opportunities across its global portfolio. The business includes an in-house R&D team that has contributed to approximately 120 launches since 2022, with a robust pipeline of new products in development."We are investing
More news about: Platinum Equity
Jul 23, 2026, 00:01 ET GHIT Fund Invests Approx. JPY 140 Million in a Portable Rapid Diagnostic System for Ebola Disease in a Joint Project Between Osaka Metropolitan University, K.K. DNAFORM, and INRB
pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which
More news about: GHIT Fund
Jul 23, 2026, 00:01 ET GHIT Fund Invests Approx. JPY 140 Million in a Portable Rapid Diagnostic System for Ebola Disease in a Joint Project Between Osaka Metropolitan University, K.K. DNAFORM, and INRB
pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which
More news about: GHIT Fund